Search the Newsreel

Assured Guaranty (NYSE:AGO) Posts Quarterly Earnings Results, Misses Expectations By $0.28 EPS

Assured Guaranty (NYSE:AGO) reported its quarterly earnings, posting an EPS of $1.23, which missed analyst consensus estimates of $1.51 by $0.28. The company's revenue saw a 30.6% year-over-year decline, though it maintained a net margin of 40.45%. Despite the earnings miss, the company declared …

Trivago N.V. ADS (NASDAQ:TRVG) Price Target Raised to $5.50

Susquehanna has increased its price target for Trivago N.V. ADS (NASDAQ:TRVG) from $3.25 to $5.50, while maintaining a "neutral" rating, suggesting a potential upside of 6.18%. Despite this, analyst sentiment remains cautious, with a consensus rating of "Reduce" and an average price target of …

Chicago Atlantic BDC (LIEN) Q1 2025 Earnings Report - Results, Call & Slides

Agora, Inc. to Report Second Quarter 2026 Financial Results on August 13, 2026

Agora, Inc. (NASDAQ: API) announced it will report its second quarter 2026 financial results on August 13, 2026, after the close of U.S. markets. The company will host a conference call on the same day at 6 p.m. Pacific Time / 9 p.m. Eastern …

Assured Guaranty (NYSE:AGO) Misses Q2 CY2026 Revenue Estimates

Assured Guaranty (NYSE:AGO) Misses Q2 CY2026 Revenue Estimates Financial guaranty insurer Assured Guaranty (NYSE:AGO) missed Wall Street's revenue expectations in Q2 CY2026, with sales falling 30.6% year on year to $195 million. Its non-GAAP profit of $1.23 per share was 23.2% below analysts' consensus …

Assured Guaranty (AGO) Q2 Earnings Lag Estimates

Assured Guaranty (AGO) came out with quarterly earnings of $1.23 per share, missing the Zacks Consensus Estimate of $1.66 per share. This compares to earnings of $1.01 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an …

Agomab Reports Half Year 2026 Financial Results and Confirms 2026 Outlook

Agomab Therapeutics NV reported its financial results for the first half of 2026, confirming its outlook for the second half of the year. The company successfully completed its Nasdaq IPO, raising $208 million, which is expected to fund operations into the first half of …

Assured Guaranty posts $39M Q2 net income, adjusted operating EPS $1.23; ABV $189.72

Assured Guaranty reported a net income of $39 million for Q2 2026, with an adjusted operating income of $55 million, or $1.23 per diluted share. The company's adjusted book value per share stood at $189.72 as of June 30, 2026. Assured Guaranty returned $62 …

Dragon Mining investors back Hong Kong holding shift, court approval pending

Earnings Flash (PTGX) Protagonist Therapeutics, Inc. Reports Q2 Revenue $213.5M, Vs. FactSet Est of $199.8M

Protagonist Therapeutics, Inc. (PTGX) announced its Q2 revenue of $213.5 million, surpassing the FactSet estimate of $199.8 million. This report highlights a stronger-than-expected financial performance for the quarter.

Citigroup Forecasts Strong Price Appreciation for Protagonist Therapeutics (NASDAQ:PTGX) Stock

Citigroup has raised its price target for Protagonist Therapeutics (NASDAQ:PTGX) to $175 from $130, maintaining a "buy" rating and implying a 19.78% upside. The company recently exceeded quarterly earnings expectations, reporting $2.29 EPS against $2.24 expected, and revenues of $213.47 million. Despite positive analyst …

Assured Guaranty Ltd. Reports Results for Second Quarter 2026

GAAP Highlights: Net income attributable to Assured Guaranty Ltd. was $39 million, or $0.88 per share,(1) for second quarter 2026. Shareholders' equity attributable to Assured Guaranty Ltd. per share was $126.18 as of June 30, 2026. Gross written premiums (GWP) were $81 million for …

Agomab Therapeutics (Nasdaq: AGMB) raises $208M IPO, funds pipeline to 2029

Agomab Therapeutics, a clinical-stage biopharmaceutical company, reported a net loss of €30.97 million for the first half of 2026 but secured its financial future by raising $208 million in gross proceeds from a Nasdaq IPO. This capital infusion, bringing their total cash and investments …

Chicago Atlantic Real Estate Finance (NASDAQ:REFI) Lowered to "Hold" Rating by Zacks Research

Zacks Research has downgraded Chicago Atlantic Real Estate Finance (NASDAQ:REFI) from a "strong buy" to a "hold" rating, while Weiss Ratings also cut its rating to "sell." The company now holds an overall "Reduce" consensus rating with an average price target of $14.00. REFI …

Agomab reports €252M cash and expects runway into H1 2029

Agomab (Nasdaq: AGMB) reported a net loss of €31.0 million for the first half of 2026, with €252.0 million in cash and short-term investments as of June 30, 2026. This cash position, bolstered by a $208 million IPO, is expected to fund operations into …

Protagonist Therapeutics stock hits all-time high at 143.43 USD

Protagonist Therapeutics (PTGX) stock has reached an all-time high of $143.43, reflecting strong investor confidence and a 155% return over the past year. The biotech firm, with an $8.83 billion market cap, is projected to see significant revenue growth and profitability by 2026, despite …

PROTAGONIST THERAPEUTICS, INC. : LEERINK PARTNERS RAISES TARGET PRICE TO $150.00 FROM $110.00

Leerink Partners has increased its target price for Protagonist Therapeutics, Inc. to $150.00, up from the previous $110.00. This adjustment reflects an updated outlook from the financial firm regarding the biotechnology company. The information was reported by Reuters.

Ceragon Networks Ltd. (CRNT) stock price, news, quote and history

Assured Guaranty earnings on deck: Can insurer sustain Q1 momentum? By Investing.com

Assured Guaranty Ltd. is preparing to release its second-quarter earnings, with analysts anticipating a significant sequential decline in profitability compared to its strong first quarter. Investors will be focused on whether this drop reflects normal volatility or deteriorating fundamentals, market share trends, and the …

PTGX Maintained by Barclays -- Price Target Raised to $153

Barclays has maintained an "Overweight" rating on Protagonist Therapeutics (PTGX), increasing its price target to $153 from $151. Despite this cautious optimism from analysts, Protagonist Therapeutics is considered significantly overvalued with a GF Value of $72.54 against its current price of $144.87, and insider …

Protagonist Therapeutics (NASDAQ:PTGX) Hits New 12-Month High Following Strong Earnings

Ceragon Networks Ltd. (CRNT) Interactive Stock Chart

This Yahoo Finance page provides an interactive stock chart for Ceragon Networks Ltd. (CRNT), along with real-time stock quotes, news, and related tickers. The article highlights recent company news including earnings announcements, significant orders from India, and new customer contracts, indicating ongoing business momentum.

B. Riley Adjusts Price Target on trivago to $8 From $6, Maintains Buy Rating

B. Riley has increased its price target for trivago (TRVG) shares to $8 from $6, while reiterating a Buy rating on the stock. This adjustment reflects a positive outlook on the online hotel search platform. The article also notes other recent analyst actions and …

Protagonist Therapeutics earnings beat by $0.16, revenue topped estimates

trivago (NasdaqGS:TRVG) Stock Faces Profit Questions Despite Stronger Revenue

Trivago's stock (NasdaqGS:TRVG) declined despite a 21% increase in Q2 revenue, reaching €168.4 million, and the company returning to profitability over the trailing twelve months with €13.1 million in earnings. However, a quarterly net loss of €5.2 million and concerns about marketing spend and …

Assured Guaranty sets Sept. 3 date for quarterly dividend

Assured Guaranty Ltd. (NYSE: AGO) has declared a quarterly dividend of $0.38 per common share. The dividend is scheduled to be paid on September 3, 2026, to shareholders who are on record as of the close of business on August 20, 2026. Assured Guaranty …

OceanaGold (NYSE: OGC) posts $647.3M revenue and $222.2M Q2 profit

Pacer Advisors Inc. Takes $4.88 Million Position in Winnebago Industries, Inc. $WGO

Pacer Advisors Inc. has acquired a new position in Winnebago Industries, Inc. (NYSE:WGO), purchasing 157,544 shares valued at approximately $4.88 million during the first quarter. This makes Pacer Advisors Inc. a 0.56% stakeholder in the RV manufacturer, while other institutional investors also increased their …

Earnings Preview: REFI to Report Financial Results Pre-market on August 11

REFI is scheduled to report its financial results pre-market on August 11. The article provides details on the company's past earnings performance, analyst estimates for the upcoming quarter, and a look at its price performance and analyst ratings. Investors will be watching for the …

Should Assured Guaranty’s (AGO) Q2 Earnings Miss Versus Expectations Require Action From Investors?

Assured Guaranty (AGO) reported Q2 earnings of US$1.01 per share, missing the Wall Street consensus expectation of US$1.56 per share. The article discusses how this earnings miss, alongside ongoing share repurchase programs and investor focus on loss reserves and credit quality, may influence the …

Trivago N.V. ADS (NASDAQ:TRVG) Price Target Raised to $8.00

Susquehanna has increased its price target for Trivago N.V. ADS (NASDAQ:TRVG) from $3.25 to $5.50, while maintaining a "neutral" rating, suggesting a potential upside of 6.18%. Despite this, analyst sentiment remains cautious, with a consensus rating of "Reduce" and an average price target of …

Golden Dragon Mining (ASX:GDR) Gains Strategic Backing as Chengtun Invests in Cue Gold Project

Tetragon Financial Group Limited Announcement of Tender Offer to Purchase $50,000,000 of Tetragon Non-Voting Shares

LONDON, Aug. 6, 2026 /PRNewswire/ -- Tetragon today announces the commencement of a tender offer to purchase a portion of its outstanding non-voting shares for a maximum aggregate payment of $50,000,000 in cash. The tender offer, which was initially announced by Tetragon on 29 …

We Think AgomAb Therapeutics (NASDAQ:AGMB) Can Afford To Drive Business Growth

AgomAb Therapeutics (NASDAQ:AGMB), despite being unprofitable, is considered to have a manageable cash burn. With €117m in cash reserves and a burn rate of €52m per year, the company has a cash runway of about 2.3 years. While its cash burn increased by 8.9% …

PROTAGONIST THERAPEUTICS, INC. : CITIGROUP RAISES TARGET PRICE TO $175 FROM $130

Citigroup has raised its target price for Protagonist Therapeutics, Inc. to $175 from $130. This update indicates a significant increase in the analyst's valuation of the company. The article, sourced from Reuters, briefly notes this financial adjustment.

Protagonist Therapeutics, Inc 2026: Revenue $213.48M, EPS $2.29— 10-Q Summary

Protagonist Therapeutics, Inc reported significantly increased revenue of $213.48M and diluted EPS of $2.29 for the 2026 quarter, largely due to license and collaboration revenue from a Takeda opt-out payment and a J&J milestone. The company achieved a net income of $162.85M compared to …